Technical Analysis for EXAS - Exact Sciences Corporation
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 63.24 | -0.46% | -0.29 |
Earnings due: May 7
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Flat | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 50 DMA | Bearish | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Crossed Above 50 DMA | Bullish | -0.46% | |
Oversold Stochastic | Weakness | -0.46% | |
MACD Bearish Centerline Cross | Bearish | 1.33% | |
Inside Day | Range Contraction | 1.33% | |
Oversold Stochastic | Weakness | 1.33% |
Alert | Time |
---|---|
Possible NR7 | about 15 hours ago |
Possible Inside Day | about 15 hours ago |
50 DMA Support | about 19 hours ago |
Fell Below 50 DMA | about 20 hours ago |
Up 1% | about 20 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/07/2024
Exact Sciences Corporation Description
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing diagnostic screening products for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company's stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with Mayo Clinic for developing tests to detect other gastro-intestinal cancers, primarily esophageal and pancreatic cancer. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Cancer Colorectal Cancer Pancreatic Cancer Medical Test Lab Testing Inflammatory Bowel Disease Polyp Molecular Diagnostics Cancer Screening Genzyme Mayo Clinic
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 100.76 |
52 Week Low | 56.05 |
Average Volume | 2,577,828 |
200-Day Moving Average | 70.48 |
50-Day Moving Average | 63.36 |
20-Day Moving Average | 68.14 |
10-Day Moving Average | 65.03 |
Average True Range | 3.04 |
RSI (14) | 44.13 |
ADX | 21.17 |
+DI | 23.82 |
-DI | 25.73 |
Chandelier Exit (Long, 3 ATRs) | 70.50 |
Chandelier Exit (Short, 3 ATRs) | 69.49 |
Upper Bollinger Bands | 76.88 |
Lower Bollinger Band | 59.40 |
Percent B (%b) | 0.22 |
BandWidth | 25.65 |
MACD Line | -0.47 |
MACD Signal Line | 0.63 |
MACD Histogram | -1.1046 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 64.83 | ||||
Resistance 3 (R3) | 65.00 | 64.64 | 64.57 | ||
Resistance 2 (R2) | 64.64 | 64.24 | 64.56 | 64.48 | |
Resistance 1 (R1) | 63.94 | 63.98 | 63.76 | 63.77 | 64.39 |
Pivot Point | 63.58 | 63.58 | 63.49 | 63.50 | 63.58 |
Support 1 (S1) | 62.88 | 63.18 | 62.70 | 62.71 | 62.09 |
Support 2 (S2) | 62.52 | 62.92 | 62.44 | 62.00 | |
Support 3 (S3) | 61.82 | 62.52 | 61.92 | ||
Support 4 (S4) | 61.65 |